Suboxone Tooth Decay Lawsuit 2025 | Claims, Payouts & Legal Updates

The Suboxone Tooth Decay Lawsuit 2025 highlights the growing wave of claims from individuals who developed severe dental damage after using Suboxone film for opioid addiction treatment. Plaintiffs allege that the manufacturer, Indivior, failed to adequately warn patients about the risk of tooth decay, erosion, and other oral injuries. This ongoing litigation includes federal multidistrict proceedings, bellwether trials, and evolving settlement discussions. On this page, you will find the latest legal updates, key case developments, timelines, and insights into potential payouts. Our guide explains how these lawsuits are progressing and what plaintiffs need to know to protect their rights.

What Is the Suboxone Tooth Decay Lawsuit?

The Suboxone tooth decay lawsuit refers to a growing group of legal claims filed by individuals who used Suboxone in its dissolvable film form and later developed serious dental injuries. Suboxone is a prescription medication that combines buprenorphine and naloxone. It is widely used to treat opioid use disorder because it helps reduce cravings and withdrawal symptoms. The dissolvable film version of Suboxone is placed under the tongue or inside the cheek, where it slowly dissolves. Patients have used this medication for many years, often as part of long-term recovery programs.

The central allegation in the lawsuit is that the manufacturers of Suboxone did not properly warn patients and healthcare providers about the significant risk of dental harm associated with the film formulation. Many people who used the medication claim that they developed extensive tooth decay, rapid enamel loss, severe cavities, oral infections, gum disease, cracked teeth, and, in many cases, complete tooth loss. Many of these individuals report that they did not have serious dental problems before taking Suboxone and that the damage progressed very quickly after they began using the film.

Plaintiffs argue that the sublingual film was designed in a way that exposed their teeth to prolonged acidity each time the film dissolved. This acidic environment, combined with the requirement to hold the film in the mouth for an extended period, could weaken and damage tooth enamel. The lawsuit claims that the manufacturers knew or should have known that this method of delivery created conditions that could harm a person’s teeth, yet they failed to provide strong and clear warnings on the product’s label or in patient information materials for many years.

People filing these lawsuits also assert that the manufacturer had access to adverse event reports and internal information that signaled a possible connection between Suboxone film and dental injury. Despite this, they argue that meaningful warnings were not issued until the United States Food and Drug Administration released a safety communication in 2022 that formally acknowledged reports of dental injuries linked to buprenorphine medicines that dissolve in the mouth.

The lawsuit is significant because many of the reported injuries are severe and expensive to treat. Patients often require crowns, root canals, extractions, implants, dentures, or full dental reconstruction. Beyond the financial burden, these dental injuries can affect a person’s ability to speak, eat, and work, and they often lead to emotional distress, embarrassment, and long-term physical discomfort.

The claims have grown large enough that cases filed across the United States have been consolidated into a multidistrict litigation proceeding in federal court. This structure is used when many people allege similar injuries from the same product. It allows the court to coordinate pretrial proceedings, including the exchange of evidence and expert testimony. Although many lawsuits are active, there has not yet been a global settlement for dental injury claims, and the litigation is continuing through various stages.

How Suboxone Causes Tooth Decay: Science & Safety Concerns

The concern surrounding Suboxone and tooth decay centers on the way the medication is formulated and administered. Suboxone is commonly prescribed in the form of a thin film that dissolves either under the tongue or between the cheek and gum. Although this method allows the medication to enter the bloodstream quickly and helps people manage opioid dependence more effectively, it also places the active ingredients and the film’s acidic components in direct and prolonged contact with the teeth. Over months and years of consistent use, this exposure can cause significant damage.

The Acidic Nature of the Suboxone Film

One of the primary scientific concerns is the pH level of the Suboxone film. The film is formulated to dissolve inside the mouth, and in order for that to happen consistently and safely, the product contains acidic substances. These acids help stabilize the medication and allow it to break down properly once placed in the mouth. However, teeth and enamel are vulnerable to repeated exposure to low pH environments.

Tooth enamel is the protective outer layer of each tooth. When enamel is exposed to acidic substances again and again, the acids begin to dissolve the minerals inside the enamel. This process is known as demineralization. Over time, demineralization weakens the tooth structure, creates soft spots, and increases the risk of cavities, fractures, and infection. The Suboxone film dissolves slowly and remains inside the mouth for an extended period, so the teeth may experience repeated acid exposure many times every day.

Prolonged Contact Inside the Mouth

Another significant factor is the length of time the film stays in contact with the teeth. Suboxone films do not dissolve instantly. Instead, patients are instructed to let the film sit in one place until it fully dissolves. This process can take several minutes. During this time, the acidic components spread across the surface of the teeth and inside the crevices where bacteria also live. This environment makes it easier for harmful bacteria to flourish.

Bacteria that naturally live inside the mouth feed on sugars and create their own acids as part of their metabolic process. When the Suboxone film adds an additional layer of acidity, it creates a compounded effect. The harmful bacteria become more active, the acids remain in contact with the enamel longer than normal, and the teeth are placed under continuous stress.

Dry Mouth and Reduced Saliva

Another scientific explanation involves saliva. Saliva plays a crucial role in protecting teeth. It neutralizes acids, washes away food particles, and provides minerals that help repair early enamel damage. Some patients using Suboxone report experiencing dry mouth, which occurs when the salivary glands do not produce enough saliva.

When saliva is reduced, the mouth loses its natural defense system. Acids remain longer on the teeth, bacteria grow more quickly, and the enamel cannot repair itself effectively. This makes the teeth much more vulnerable to rapid decay.

Repetitive Daily Exposure

People who take Suboxone usually take it every day, and in many cases twice a day. This means their teeth are exposed to the same pattern of acidity day after day for long periods. Many individuals use Suboxone as part of a long-term recovery plan, which means that they may continue taking the medication for years. Long-term exposure is one of the reasons dental injuries can be so severe. A tooth that might tolerate occasional acidity cannot withstand it repeatedly without eventually breaking down.

The Cumulative Effect on Teeth

The combination of the acidic film, extended contact time, bacterial activity, and reduced saliva can create a powerful and harmful cycle. Each dose of Suboxone further weakens the enamel. Over time, tiny weak points in the teeth become cavities. Cavities expand, tooth structure collapses, infection develops, and teeth may crack or break entirely. Many people who have filed lawsuits describe experiencing multiple cavities at once or losing several teeth in a relatively short period, even though they previously had no serious dental issues.

Safety Concerns and the Delay in Warnings

Although the dental risks appear directly linked to the film’s chemistry and method of use, many users and healthcare providers were not made aware of these risks for many years. The delay in issuing strong warnings is an important safety concern raised in the ongoing litigation. The argument is that the manufacturer had access to information that suggested a risk but did not update the warnings until after a significant number of patients had already suffered dental damage.

In 2022, health authorities issued an official communication stating that buprenorphine medications that dissolve in the mouth may cause severe dental problems. This was the first time many patients learned there could be a connection between their medication and their dental injuries. The late timing of this notice has raised important questions about whether earlier warnings could have prevented serious and long-lasting damage.

Injuries Reported in Suboxone Tooth Damage Claims

Patients who used the dissolvable Suboxone film report a pattern of dental injuries that are unusually rapid, unusually severe, and often irreversible. These injuries form the core of the legal claims now being brought forward.

Severe and Rapid Tooth Decay

Many individuals describe sudden, aggressive decay that develops far faster than normal dental deterioration. Cavities often appear in multiple teeth at once, and decay progresses deeply before patients realize the extent of the damage.

Enamel Erosion

The acidic nature of the film is believed to weaken and dissolve the outer enamel layer. This leaves teeth fragile, exposed, and unable to protect themselves from bacteria and further damage.

Cracked and Broken Teeth

Weakened enamel often progresses to structural failure. Users report teeth cracking, breaking during routine chewing, or splitting entirely.

Tooth Loss and Extractions

For many claimants, the damage becomes so advanced that teeth cannot be saved. Some lose teeth on their own, while others undergo medically necessary extractions to prevent infection or further oral decline.

Oral Infections and Abscesses

Decay that penetrates deep into the tooth can trigger painful infections. Some patients develop abscesses that require root canal therapy, surgical intervention, or emergency treatment.

Gum Injury and Gum Disease

Inflamed gums, gum recession, and worsening periodontal disease are frequently reported, adding another layer of harm to an already deteriorating dental condition.

Extreme Tooth Sensitivity

Even before a tooth fracture, many patients develop intense sensitivity to temperature and pressure. This often signals advanced enamel erosion and underlying structural damage.

Full Mouth Reconstruction Needs

Because multiple teeth are affected at once, many individuals require extensive dental work. This can include crowns, implants, bridges, root canals, dentures, and long-term restorative care.

Emotional and Psychological Harm

Dental collapse affects far more than oral health. Many claimants face embarrassment, loss of confidence, difficulty eating, trouble speaking, and a significant decline in quality of life.

Permanent Damage

Perhaps the most striking issue is permanence. Even after stopping Suboxone film, many injuries cannot be reversed. Teeth that are lost will not grow back, and structural damage often requires lifelong treatment.

Who Is Eligible to File a Suboxone Tooth Decay Lawsuit?

A person may qualify to file a Suboxone tooth decay lawsuit if they used doctor-prescribed Suboxone dissolvable film and later experienced major dental issues, including rapid decay, enamel erosion, cavities, cracked or broken teeth, infections, gum damage, or tooth loss. The dental harm must have occurred after starting the film and must be serious enough to require professional treatment. Additionally, the individual must not have been clearly warned about these dental risks before using the medication.

How to File a Suboxone Lawsuit: Process & Required Evidence

To file a Suboxone lawsuit, a person contacts a lawyer who reviews their prescription history, dental problems, and when the injuries started. If the case qualifies, the lawyer files it within the ongoing litigation and begins gathering evidence. The evidence needed includes dental records showing decay, fractures, enamel loss, infections, or extractions, along with medical records proving Suboxone film use. Photos of the damage, dentist statements, treatment bills, and notes describing pain or functional problems also help show that the dental injuries began after using the dissolvable film.

Timeline of the Suboxone Tooth Decay Lawsuit

Track the key milestones in the Suboxone tooth decay litigation, from MDL filings and court orders to bellwether trials and settlement updates. Stay informed on how the cases are evolving and what developments may impact plaintiffs and potential payouts.

September 18, 2025 – Judge Calabrese Issues New Compliance Enforcement Order

On September 18, 2025, Judge Calabrese issued a significant enforcement order that signals a stronger push for procedural compliance within the Suboxone tooth decay litigation. This followed an in-person status conference held on September 9, where the court reviewed continuing issues involving missed deadlines, incomplete submissions, and outstanding records.

The judge made it clear that the period of leniency has ended. Both plaintiffs and third-party record providers will now face consequences if they fail to meet established requirements. Although this may sound like increased pressure on plaintiffs, many plaintiffs’ attorneys actually view the move as positive because it helps clear out inactive or noncompliant cases that slow the entire MDL.

The order requires the three remaining third-party providers to turn over medical or related records needed to assess individual claims. These records have been delayed for months despite earlier instructions. If the providers fail to comply by the end of the month, the requesting party may pursue a contempt motion under Rule 45, which permits the court to issue fines or other sanctions against noncompliant parties.

Judge Calabrese also dismissed several plaintiffs’ cases with prejudice for failing to meet requirements under Case Management Order No. 15. A dismissal with prejudice is permanent and prevents the plaintiff from refiling the claim. In large MDLs, this type of enforcement is sometimes necessary to determine which cases are viable and which are not.

To keep the litigation progressing, the court also announced that another order will be issued outlining the procedure for Census Round 2. This process will collect updated information from plaintiffs and is expected to play an important role in shaping future settlement discussions.

September 9, 2025 – Status Conference Highlights Delays in Records and Compliance

During the September 9 status conference, the court focused heavily on the ongoing delays in gathering essential records and ensuring compliance across the Suboxone litigation. The judge reviewed outstanding subpoenas issued to treatment centers and a pharmacy that have still not produced the required documents. These missing records continue to slow the evaluation of claims and the movement of cases through the MDL.

The court also examined the status of the plaintiff’s census submissions. Plaintiffs who have not completed their census forms or provided their medical records face the possibility of dismissal, as the judge stressed that cases cannot remain active without these basic requirements. The Record Collection Pool cases received particular attention as the court determined which claims have met their obligations and which may be removed from the pool.

Defense obligations were also addressed. The judge pressed for clearer guidance on document production schedules and corporate witness testimony. Ongoing disputes involving older company emails and a recent privilege clawback were raised, and the court signaled it may step in to resolve these issues to prevent further delays.

September 5, 2025 – Official MDL Filing Count Reaches 1,882 Cases

By early September, the Suboxone tooth decay MDL recorded 1,882 filings on the docket in the Northern District of Ohio. This number, however, does not accurately reflect the true size of the litigation. Case Management Order No. 14 allows plaintiffs to file in batches of up to one hundred per complaint, which means the official docket count captures only a fraction of the individuals involved.

When these batch filings are taken into account, current estimates indicate that more than twenty thousand individuals have active claims connected to Suboxone related dental injuries. The key question now is how many of these claims will ultimately qualify for compensation. Early assessments suggest that the number of viable, provable claims may represent less than half of the total filings, highlighting the importance of medical documentation, product use verification, and timely compliance with court requirements as the MDL continues to advance.

August 27, 2025 – Show-Cause Hearing for Non-Producing Record Providers

Judge Calabrese convened a short but significant show-cause hearing to address four record providers that failed to produce required documents despite multiple prior orders. Plaintiffs’ counsel explained that they had been attempting to secure these records since March 2025 through repeated phone calls, certified mail, and continued follow-up, yet none of the four providers had complied.

Because the records are essential for verifying prescription histories, plaintiffs requested that the court require the providers to cover the reasonable fees and expenses generated by these prolonged retrieval efforts. They also asked the court to consider additional sanctions in order to compel compliance.

None of the providers sent a representative to the hearing. The judge took the matter under advisement and instructed the Clerk to send the hearing minutes directly to each provider. The court’s readiness to consider penalties reflects growing frustration over stalled record production. These delays prevent plaintiffs from proving product use and slow the entire MDL. Judicial pressure is increasing to remove these bottlenecks so that the litigation can stay on track for bellwether trials and a future settlement path.

August 18, 2025 – New Batch Filing Adds 54 Additional Plaintiffs

A newly filed complaint in the Suboxone MDL brought in fifty-four additional plaintiffs from multiple states, continuing the trend of fewer overall filings but larger grouped submissions. These plaintiffs allege that Suboxone film caused significant and often permanent dental harm despite their consistent and medically supervised use of the medication.

The complaint notes that each person used Suboxone film as prescribed for opioid use disorder or, in some instances, for pain management. Over time, they developed severe dental injuries such as widespread decay, enamel erosion, infections, and tooth loss that required extensive procedures, including extractions, root canals, and full or partial dental reconstruction.

The filing asserts that the manufacturers were aware of the dental risks long before the warning was added in June 2022. According to the allegations, internal reports and published research pointed to serious oral health consequences caused by the acidic formulation of the film. Plaintiffs argue that the companies failed to revise the label through the FDA’s Changes Being Effected pathway, which permits manufacturers to strengthen warnings when new safety information emerges. Instead, they claim the manufacturers waited until the FDA demanded a formal update, leaving thousands of patients exposed to unaddressed risks.

August 10, 2025 – Court Pressures Pharmacies Over Missing Prescription Records

The court intensified its focus on one of the most persistent barriers in the Suboxone tooth decay MDL: the chronic failure of pharmacies to produce prescription records. These records form the backbone of every viable claim because they verify that a plaintiff was prescribed brand-name Suboxone film before developing dental injuries. Without them, cases cannot advance to the stages where they can be evaluated, selected for bellwethers, or considered for settlement.

Although the record collection process should be routine, it has instead become a prolonged and frustrating battle. Plaintiffs have submitted valid HIPAA authorizations, yet many pharmacies have continued to ignore subpoenas, miss deadlines, or simply refuse to provide complete prescription histories. This has created a procedural gridlock that holds hundreds of cases in place and severely limits the court’s ability to build a reliable trial pool.

Judge Calabrese responded with a sweeping show-cause order directed at nearly twenty noncompliant pharmacies. He required custodians to appear in person on August 25 and justify their failure to honor prior court orders, which mandated record production within thirty days of receiving a signed authorization. The order signals that the court’s patience has worn thin after months of repeated attempts by the plaintiffs’ steering committee to obtain cooperation.

The consequences reach far beyond administrative inconvenience. Progress toward bellwether trials depends on narrowing a pool of five hundred cases to a focused set of fifteen. That process cannot even begin until prescription verification is complete. A future global settlement is equally dependent on reliable documentation, since defendants will not negotiate without proof of product use for each plaintiff. Judge Calabrese’s latest action reflects a determination to break this logjam and keep the MDL on a path toward trials and potential resolution.

July 17, 2025 – Concerns Over Defendant’s Misjudgment of Jury Perception

There is growing concern that Indivior is misreading how juries will view Suboxone plaintiffs. The company appears to be assuming that individuals in recovery will not be seen as credible or sympathetic. This strategy depends on the belief that addiction carries enough stigma to blunt juror empathy. If that is the calculation, it is not simply mistaken. It is a profound strategic error that could expose the company to far greater financial consequences than a fair settlement would require.

The reality of these plaintiffs is very different from the stereotype Indivior may be relying on. Many are parents, employees, spouses, and community members who made a deliberate choice to seek treatment. They stayed committed to their recovery plan. They used Suboxone exactly as prescribed and trusted that it was safe. What they did not anticipate was severe and lasting dental harm that was never disclosed to them.

Their injuries are costly and life-altering. They have endured chronic pain, broken teeth, infections, and extensive dental reconstruction that often reaches into tens of thousands of dollars. Beyond the physical and financial toll, many have experienced a profound loss of confidence and well-being that comes from suffering disfiguring injuries they never could have predicted.

Juries tend to respond to honesty, responsibility, and real harm. It will not be difficult for plaintiffs’ counsel to show that these individuals took the right steps for their health and were let down by a manufacturer that failed to warn them of a known risk. Jurors are likely to understand that this was not a matter of misuse or personal failure. It was a matter of a company withholding essential safety information.

If Indivior continues to assume that jurors will discount the suffering of people in recovery, it risks misjudging the basic fairness and discernment of everyday Americans. That miscalculation could lead to verdicts that are far more costly than an early and reasonable settlement.

July 17, 2025 – Concerns Over Defendant’s Misjudgment of Jury Perception

Suboxone litigation has stayed relatively low-profile compared to other mass torts, but that may soon change. Plaintiffs in these cases include individuals in recovery who used Suboxone as prescribed and later suffered severe dental injuries with significant financial consequences. Many had no meaningful dental problems before taking the medication, which makes their stories even more compelling. As these accounts gain more visibility through media coverage or trial presentations, Indivior’s assumption that juries may be unsympathetic could become a major strategic miscalculation. A single high-impact verdict has the potential to reshape the entire litigation landscape and increase pressure for settlement.

July 11, 2025 – Suboxone Lawsuit Profile Is Changing

A new court order has reshaped how depositions will take place as the Suboxone MDL moves deeper into discovery and prepares for future bellwether trials. The judge clarified that depositions should generally occur in person, although both sides may agree to hold them remotely. When a deposition is conducted through a virtual platform, the requesting party must manage the setup, verify the identity of all participants, and ensure confidentiality protections are maintained throughout the proceeding.

The order sets detailed rules for the handling of exhibits. Lawyers are encouraged to provide materials to witnesses ahead of time when possible, particularly in remote settings, and witnesses must confirm they will not review sealed documents until the deposition officially begins. The order also addresses scheduling expectations. When plaintiffs seek to depose current or former company employees, the defense team must provide at least two available dates within ten days. Only one lawyer per side will question the witness in most cases, although plaintiffs may divide questioning between two attorneys if they give advance notice. These procedures are intended to maintain organization and efficiency as discovery expands and trial preparation intensifies.

July 8, 2025 – New Deposition Procedures Issued

The court’s latest deposition order arrives at a moment when Indivior’s defense strategy appears to rely heavily on the belief that juries will distance themselves from plaintiffs who have a history of opioid addiction. That assumption overlooks the human reality behind these cases and misjudges how jurors respond to credible personal stories. The individuals bringing these claims followed medical guidance, committed to recovery, and used Suboxone exactly as prescribed. Many later experienced catastrophic dental harm that changed the course of their lives. These are not minor complaints. They involve people in their thirties and forties who now require dentures, multiple implants, or complete dental reconstruction without having received a proper warning that could have allowed them to protect their health.

Jurors tend to respond to honesty, perseverance, and the everyday struggles that mirror their own lives. Teachers, warehouse workers, nurses, and single parents are among those stepping forward to explain how Suboxone left them unable to chew comfortably or speak confidently. Their stories carry a dignity that cuts through any attempt to lean on stigma or outdated perceptions of addiction. This context also intersects with Indivior’s history of prior criminal conduct in its marketing practices, which, even if not admitted directly into evidence, inevitably shapes how juries perceive corporate behavior.

If Indivior expects these plaintiffs to be met with skepticism, it is misreading both the litigation climate and the cultural shift in how addiction and treatment are understood. The plaintiffs’ legal teams are prepared to present strong testimony and compelling evidence. If reasonable settlement negotiations do not progress, juries will be asked to determine the value of these injuries, and the resulting awards could be far higher than any early settlement Indivior might prefer to negotiate.

July 3, 2025 – Indivior’s Blind Spot in Jury Strategy

Efforts to keep the Suboxone litigation moving have continued to be slowed by persistent problems securing pharmacy records, which are essential for proving prescription histories. Several major pharmacies were recently ordered by the court to explain why they had not complied with Case Management Order No. 13. This order requires pharmacies to provide records within thirty days after receiving valid medical authorizations, yet repeated delays have created significant bottlenecks for plaintiffs who cannot advance their cases without this documentation.

By early July, the judge withdrew the show-cause orders for two providers that finally produced the required records after intervention by Plaintiffs’ Leadership Counsel. However, the hearing remains scheduled for Walgreens Pharmacy, which has not resolved its compliance issues. The court will now require Walgreens to appear and account for its failure to meet mandatory production deadlines. This development underscores the broader challenge within the litigation, where incomplete or delayed records continue to obstruct progress toward trial preparation and settlement evaluation.

June 27, 2025 – Ongoing Battles to Obtain Pharmacy Records

The struggle to secure pharmacy records remains one of the most persistent barriers in the Suboxone litigation. These records are essential for proving when patients were prescribed Suboxone film and how long they used it before their dental injuries developed. Despite clear directives under Case Management Order No. 13, several pharmacies continue to delay or fail to produce records even after receiving properly executed medical authorizations. These gaps slow progress on the entire litigation because plaintiffs cannot advance without documentation verifying their prescription histories. The court is expected to continue tightening enforcement to ensure the record flow improves, since these materials are critical for evaluating claims and preparing for future bellwether trials.

June 5, 2025 – Plaintiff Lineup Shuffle in the 500-Case Pool

After outlining the path to the first bellwether trials in Order No. 15, the court released Second Amended Order No. 16, removing forty-eight plaintiffs from the 500-person Records Collection Pool and adding new individuals in their place.

These substitutions became necessary because some plaintiffs voluntarily dismissed their cases, while others failed to provide the required medical authorizations. The court replaced them through the same random-selection method outlined in the protocol. 

This reshuffling matters because the 500-person pool serves as the foundation for the groups that will later be narrowed to 100, then 50, then 15, and eventually the final group of trial-ready plaintiffs. The replacement process helps preserve the integrity and momentum of the bellwether structure.

May 24, 2025 – Bellwether Trial Protocol Established

The court issued Amended Case Management Order No. 15, creating the official bellwether framework for the Suboxone multidistrict litigation. The order established a multistage process that begins with the selection of a 500-plaintiff Records Collection Pool. Every plaintiff in this group must supply signed medical authorizations that allow lawyers to gather Suboxone treatment records and documentation of dental injuries. Plaintiffs who do not comply may be dismissed and replaced immediately to maintain the size and continuity of the pool. From this initial group, one hundred cases will be randomly selected for the Core Discovery Pool, where both sides will exchange detailed fact sheets, records, and other foundational materials. 

That group will then be narrowed to fifty cases through a combination of random selection and lawyer nominations. After depositions and deeper discovery, fifteen cases will move into the Trial Pool, with five chosen by each side and five at random. Finally, six potential bellwether cases will be identified, and each side will strike one to leave four that may proceed to trial. This structured process is designed to guide the litigation toward meaningful test trials and to create pressure that could encourage a broader Suboxone settlement.

March 13, 2025: Reduction in Schedule A Claims

Shortly after the Suboxone MDL was created, the approaching statute of limitations in states with a two-year deadline triggered a surge in filings ahead of June 2024. To prevent the court from being overwhelmed and to spare plaintiffs’ counsel from unnecessary filing fees, Judge Calabrese permitted a consolidated action known as the Schedule A cases. This group consisted of roughly 9,600 individuals, many of whom were still gathering the documentation needed to support their claims.

In recent weeks, the number of Schedule A complaints has dropped to 8,611, reflecting the removal of claims that attorneys initially preserved but later determined were not viable. A new order is expected this week to address the next statute of limitations deadline and prevent another wave of rushed filings.

November 23, 2024: Addressing Duplicate Legal Representation

Many Suboxone claimants have retained more than one lawyer. One major takeaway from Thursday’s status conference was the need for attorneys to use the Rubris Crosslink platform, first discussed in the November 15 update, to begin resolving this problem. Duplicate representation creates conflicts, slows case progress, and can complicate settlement negotiations if not addressed early.

Rubris Crosslink provides a centralized system that identifies clients who appear in more than one law firm’s records. This allows firms to resolve overlapping representation quickly and streamline case management. This issue is not unique to Suboxone litigation. It is common across mass torts and usually results from misunderstandings, aggressive marketing, or the mistaken belief that hiring multiple firms improves outcomes.

October 4, 2024: Two-Day Status Conference and Bellwether Planning

A rare two-day status conference is underway in the Suboxone MDL, and the key issue for current and prospective plaintiffs is the development of a bellwether trial plan.

Bellwether trials serve as the first trials in mass tort litigation and help determine how juries may react to the evidence and arguments presented by both sides. These early cases will address issues common across most Suboxone claims, such as alleged design defects, insufficient warnings, and misleading marketing.

The outcomes of these trials often influence settlement discussions because they provide insight into potential liability and exposure for the defendants. There is a strong chance the defendants may seek to settle before any bellwether trial begins, given the risks associated with jury verdicts. Still, setting trial dates is crucial, as firm deadlines create pressure. The earlier these trials are scheduled, the sooner substantive Suboxone settlement negotiations are likely to progress.

September 23, 2024: Why Lawyers Prioritize Pre-June 2018 Suboxone Use

The Suboxone lawsuits primarily focus on brand-name Suboxone use before June 2018. During that period, Indivior, the company responsible for designing, testing, and producing Suboxone, controlled most of the market.

After June 2018, generic versions became widely available and quickly captured most of the market share. The current Suboxone tooth decay litigation centers on the brand-name drug, with plaintiffs alleging that its defective design led to severe dental injuries such as tooth decay, erosion, and tooth loss.

Suing generic manufacturers is possible, but it is far more challenging. Supreme Court precedent largely shields generic drug makers from failure-to-warn claims, which are the primary claims in this MDL. Under FDA rules, generic manufacturers are required to copy the brand-name labeling exactly. They cannot independently modify or add warnings, even if new risks become apparent.

Because they must follow the brand-name label, courts have consistently ruled that generic companies cannot be held liable for not adding warnings beyond what the brand-name manufacturer already includes. As a result, Suboxone plaintiffs are limited primarily to targeting Indivior, even when they were injured after taking the generic form of the product.

September 13, 2024: The Severity of Dental Injuries Comes Into Focus

The evidence will likely show that Indivior knew Suboxone could cause tooth decay and chose not to add a warning to protect sales, fearing that a warning would discourage doctors from prescribing the medication.

However, the severity of dental injuries reported in this litigation appears to have surprised Indivior, Aquestive, and even many plaintiffs’ lawyers. The extent of the decay and the life-altering impact it has had on victims is significant. The mouth is not built to withstand the continual exposure to chemical compounds designed to treat addiction while silently creating another problem in the form of catastrophic dental damage.

February 4, 2024: JPML Creates the Suboxone MDL

The Judicial Panel on Multidistrict Litigation has created a new Suboxone MDL, consolidating federal lawsuits alleging that the manufacturers of Suboxone film failed to warn consumers that the medication contains components that can cause dental decay.

Fifteen Suboxone lawsuits from five judicial districts have been transferred to the Northern District of Ohio. Judge J. Philip Calabrese will oversee the proceedings.

The MDL is titled In re: Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, case number 1:24-md-03092.

January 30, 2024: Statute of Limitations Concerns and State Variations

The statute of limitations has been a significant concern in the Suboxone litigation. If you are having difficulty reaching a lawyer, it may be because you reside in a state where the two-year limitations period creates risk for new cases. The deadline in mass tort litigation is rarely straightforward. For example, if dental injuries surfaced more recently, that timing may extend the filing period. Some attorneys argue that the limitations clock has not even started because Suboxone’s warning label remains inadequate.

Still, as of this date, most Suboxone lawyers, including our firm, were limiting new cases to certain states because of statute-of-limitations concerns.

Those states included: 

• North Dakota
• Connecticut
• Florida
• Maine
• Missouri
• Washington
• New Hampshire
• Arkansas
• Texas
• Maryland
• Wyoming
• New Jersey
• Rhode Island
• Nebraska
• South Carolina
• Montana
• Washington, D.C.
• Mississippi
• Utah
• Vermont
• New Mexico
• New York
• Wisconsin
• Virginia
• North Carolina
• Massachusetts

January 22, 2024: New Case Highlights Discovery Rule Issues

A newly filed Suboxone lawsuit illustrates how the discovery rule may preserve claims that appear to fall outside the statute of limitations.

The plaintiff lives in Mt. Sterling, Kentucky. He was prescribed Suboxone film in 2011 for opioid use disorder and later developed significant tooth decay. He alleges that he did not discover the cause of his dental injuries until late 2023.

Kentucky has a strict one-year statute of limitations, which would normally bar his claim. However, the discovery rule allows the filing period to begin when the plaintiff knew or reasonably should have known of both the injury and its connection to the defendant’s product.

Because he filed his lawsuit within one year of learning that Suboxone caused his dental injuries, his claim will serve as an important example of how courts may apply the discovery rule to Suboxone litigation.

Current Legal Developments and Court Updates

Current legal developments show that the Suboxone tooth-decay lawsuits are now consolidated into MDL 3092 in the Northern District of Ohio, where roughly 1,871 cases are currently active. Discovery is underway, with plaintiffs required to submit dental and medical records, while defendants must produce internal safety and marketing documents. The court has issued multiple case-management orders to keep the litigation moving, but no global settlement has been announced yet. Bellwether trials are expected later, which will help shape potential settlement negotiations.

What Comes Next in the Suboxone Tooth Decay Litigation?

The Suboxone tooth decay lawsuits are now moving into a more structured and intensive stage of the MDL process. The court is working to organize the large number of claims, refine the evidence that will be used, and select the first group of cases that will be prepared for trial. These steps will shape how the litigation develops, how strong the plaintiffs’ position becomes, and how soon meaningful settlement discussions may begin. The next phase is centered on documentation, expert review, and determining which cases best represent the broader group of claimants.

Key developments that come next include:

• The litigation continues under MDL 3092 in the Northern District of Ohio, where all federal Suboxone tooth decay lawsuits have been centralized.
• The court is now selecting a structured group of plaintiffs, beginning with a Records Collection Pool of about 500 individuals, which will be narrowed down step by step until only a small sample of trial-ready bellwether cases remains.
• Discovery is intensifying, with both sides exchanging medical and dental records, internal company documents, deposition testimony, and expert evaluations.
• The court is issuing show-cause orders to any plaintiffs or third-party providers who fail to meet deadlines for supplying records or complying with case management requirements.
• A global settlement has not yet been reached, and significant negotiations are expected only after the bellwether trials provide clarity on how juries may react to the evidence.
• Plaintiffs are encouraged to gather dental records, medical history, treatment bills, photographs, and a clear timeline of Suboxone use, because the upcoming trial selection process will rely heavily on the strength and completeness of documented evidence.

Frequently Asked Questions on the Suboxone Tooth Decay Lawsuit